• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

功能评定量表2.0(FuRST 2.0):一种患者自我报告的亨廷顿舞蹈病功能结局测量方法。

Functional Rating Scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington's disease.

作者信息

Fuller Rebecca Lm, Feigenbaum Pua, LaPelle Nancy, Sathe Swati, Dalal Prachi, Vaidya Jatin G, Sinha Neha, Roché Matthew, Fitzer-Attas Cheryl J, Sampaio Cristina, Stebbins Glenn T

机构信息

CHDI Management, Inc., the company that manages the scientific activities of CHDI Foundation, Inc., Princeton, NJ, USA.

Qualitative Research and Evaluation Consulting, Westborough, MA, USA.

出版信息

J Huntingtons Dis. 2025 May;14(2):171-178. doi: 10.1177/18796397251323549. Epub 2025 Apr 15.

DOI:10.1177/18796397251323549
PMID:40232155
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12231842/
Abstract

BackgroundCurrent functional rating scales are not sensitive to the earliest functional changes in Huntington's disease (HD).ObjectiveThe Functional Rating Scale 2.0 (FuRST 2.0) is a patient-reported outcome (PRO) measure designed to be sensitive to the initial functional changes in HD, specifically stage 2 and mild stage 3, as defined by the Huntington's Disease Integrated Staging System (HD-ISS).MethodsWe followed standard assessment development methodology to create a PRO. Study 1 consisted of a Delphi panel which analyzed data from focus groups comprised of people with HD and companions from 6 countries. This was followed by four rounds of cognitive interviews through which we evaluated respondents' comprehension of the instructions, understanding of question and response options, and comfort with the material. Informal advice from a regulatory agency was garnered throughout the process.ResultsConcerns from the target population and regulators regarding instructions, questions, response options, and comfort with the material were addressed through modifications to the scale's wording and format.ConclusionsWe developed the FuRST 2.0 official working document (OWD), the penultimate version of the scale, using focus groups, a Delphi panel, iterative rounds of cognitive interviewing, and informal regulatory advice. Its psychometric properties are being evaluated in the FOCUS-HD validation studies from which the final version of the scale will be derived. The FuRST 2.0 OWD is available for use.

摘要

背景

目前的功能评定量表对亨廷顿舞蹈病(HD)最早出现的功能变化并不敏感。

目的

功能评定量表2.0(FuRST 2.0)是一种患者报告结局(PRO)测量工具,旨在对HD早期的功能变化敏感,特别是亨廷顿舞蹈病综合分期系统(HD-ISS)所定义的2期和轻度3期。

方法

我们遵循标准的评估开发方法来创建一个PRO。研究1包括一个德尔菲小组,该小组分析了来自6个国家的HD患者及其同伴组成的焦点小组的数据。随后进行了四轮认知访谈,通过这些访谈我们评估了受访者对指导语的理解、对问题和回答选项的理解以及对材料的接受程度。在整个过程中都获取了监管机构的非正式建议。

结果

通过对量表的措辞和格式进行修改,解决了目标人群和监管机构对指导语、问题、回答选项以及对材料接受程度的担忧。

结论

我们使用焦点小组、德尔菲小组、多轮迭代认知访谈以及监管机构的非正式建议,开发了FuRST 2.0官方工作文件(OWD),即该量表的倒数第二个版本。其心理测量特性正在FOCUS-HD验证研究中进行评估,量表的最终版本将从中得出。FuRST 2.0 OWD可供使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212c/12231842/de2c3c861eca/10.1177_18796397251323549-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212c/12231842/03e45c00f2f5/10.1177_18796397251323549-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212c/12231842/8b73dc3e89ba/10.1177_18796397251323549-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212c/12231842/de2c3c861eca/10.1177_18796397251323549-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212c/12231842/03e45c00f2f5/10.1177_18796397251323549-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212c/12231842/8b73dc3e89ba/10.1177_18796397251323549-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212c/12231842/de2c3c861eca/10.1177_18796397251323549-fig3.jpg

相似文献

1
Functional Rating Scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington's disease.功能评定量表2.0(FuRST 2.0):一种患者自我报告的亨廷顿舞蹈病功能结局测量方法。
J Huntingtons Dis. 2025 May;14(2):171-178. doi: 10.1177/18796397251323549. Epub 2025 Apr 15.
2
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
3
A New Measure of Quantified Social Health Is Associated With Levels of Discomfort, Capability, and Mental and General Health Among Patients Seeking Musculoskeletal Specialty Care.一种新的量化社会健康指标与寻求肌肉骨骼专科护理的患者的不适程度、能力以及心理和总体健康水平相关。
Clin Orthop Relat Res. 2025 Apr 1;483(4):647-663. doi: 10.1097/CORR.0000000000003394. Epub 2025 Feb 5.
4
Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa.使用比美吉珠单抗治疗化脓性汗腺炎的III期BE HEARD I和II试验的汇总数据,对化脓性汗腺炎生活质量(HiSQOL©)问卷进行心理测量学验证和解释阈值分析。
Br J Dermatol. 2025 Jun 20;193(1):93-104. doi: 10.1093/bjd/ljaf067.
5
Selegiline for Alzheimer's disease.司来吉兰用于治疗阿尔茨海默病。
Cochrane Database Syst Rev. 2003(1):CD000442. doi: 10.1002/14651858.CD000442.
6
Exercise interventions and patient beliefs for people with hip, knee or hip and knee osteoarthritis: a mixed methods review.髋、膝或髋膝骨关节炎患者的运动干预和患者信念:一项混合方法综述
Cochrane Database Syst Rev. 2018 Apr 17;4(4):CD010842. doi: 10.1002/14651858.CD010842.pub2.
7
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.社区居住的老年人跌倒预防干预措施:系统评价和荟萃分析的益处、危害以及患者的价值观和偏好。
Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3.
8
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
9
Is It Possible to Develop a Patient-reported Experience Measure With Lower Ceiling Effect?是否有可能开发一种天花板效应较低的患者报告体验测量方法?
Clin Orthop Relat Res. 2025 Apr 1;483(4):693-703. doi: 10.1097/CORR.0000000000003262. Epub 2024 Oct 25.
10
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.

本文引用的文献

1
Defining Clinical Meaningfulness in Huntington's Disease.定义亨廷顿病的临床意义。
Mov Disord. 2023 Jun;38(6):1036-1043. doi: 10.1002/mds.29394. Epub 2023 May 5.
2
A biological classification of Huntington's disease: the Integrated Staging System.亨廷顿病的生物学分类:综合分期系统。
Lancet Neurol. 2022 Jul;21(7):632-644. doi: 10.1016/S1474-4422(22)00120-X.
3
A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility.FDA 批准新药的患者报告结局标签回顾(2016-2020 年):数量、类别和可理解性。
Value Health. 2022 Apr;25(4):647-655. doi: 10.1016/j.jval.2021.10.006. Epub 2021 Dec 24.
4
Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration.美国食品和药物管理局批准的孤儿药标签中的患者报告结局。
Value Health. 2019 Aug;22(8):925-930. doi: 10.1016/j.jval.2019.03.010. Epub 2019 May 17.
5
Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations.用于评估亨廷顿舞蹈症功能能力的评定量表和基于表现的测量方法:批判与建议
Mov Disord Clin Pract. 2018 May 9;5(4):361-372. doi: 10.1002/mdc3.12617. eCollection 2018 Jul-Aug.
6
Best Practices for Developing and Validating Scales for Health, Social, and Behavioral Research: A Primer.健康、社会和行为研究量表开发与验证的最佳实践:入门指南。
Front Public Health. 2018 Jun 11;6:149. doi: 10.3389/fpubh.2018.00149. eCollection 2018.
7
Code Saturation Versus Meaning Saturation: How Many Interviews Are Enough?代码饱和度与意义饱和度:多少次访谈才算足够?
Qual Health Res. 2017 Mar;27(4):591-608. doi: 10.1177/1049732316665344. Epub 2016 Sep 26.
8
Assessment of Day-to-Day Functioning in Prodromal and Early Huntington Disease.前驱期和早期亨廷顿病日常功能评估
PLoS Curr. 2011 Sep 12;3:RRN1262. doi: 10.1371/currents.RRN1262.
9
Huntington's disease: a clinical review.亨廷顿病:临床综述。
Orphanet J Rare Dis. 2010 Dec 20;5:40. doi: 10.1186/1750-1172-5-40.
10
Challenges assessing clinical endpoints in early Huntington disease.评估亨廷顿病早期临床终点的挑战。
Mov Disord. 2010 Nov 15;25(15):2595-603. doi: 10.1002/mds.23337.